RedHill Biopharma (RDHL) Cash from Operations (2012 - 2023)

RedHill Biopharma (RDHL) has reported Cash from Operations for 12 consecutive years, with -$10.6 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Cash from Operations rose 36.14% year-over-year to -$10.6 million in Q2 2023; TTM through Jun 2023 was -$26.2 million, a 51.99% increase from a year earlier, with the FY2025 full-year figure at -$9.7 million, down 3.01% from the prior year.
• Cash from Operations was -$10.6 million for Q2 2023 at RedHill Biopharma, down from -$7.2 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$2.4 million in Q4 2022 and troughed at -$19.0 million in Q3 2021.
• A 5-year average of -$11.1 million and a median of -$10.6 million in 2020 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations sank 107.45% in 2021 and jumped 83.71% in 2022, its largest moves.
• Over 5 years, Cash from Operations stood at -$13.9 million in 2019, then grew by 8.39% to -$12.7 million in 2020, then retreated by 16.95% to -$14.9 million in 2021, then jumped by 83.71% to -$2.4 million in 2022, then plunged by 337.38% to -$10.6 million in 2023.
• The last three Cash from Operations figures came in at -$10.6 million (Q2 2023), -$7.2 million (Q1 2023), and -$2.4 million (Q4 2022), per Business Quant data.